Voxtalisib

Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43 nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=157 nM) . Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.

Product Specifications

CAS Number

[934493-76-2]

Product Name Alternative

XL765; SAR245409

UNSPSC

12352005

Hazard Statement

H302

Target

MTOR; PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SAR245409.html

Purity

99.82

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

O=C1C(C2=NNC=C2)=CC3=C(C)N=C(N)N=C3N1CC

Molecular Formula

C13H14N6O

Molecular Weight

270.29

Precautions

H302

References & Citations

[1]Garcia-Echeverria C, et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008 Sep 18;27 (41) :5511-26.|[2]Yu P, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13 (5) :1078-91.